A fast growing sector with strong products and players – but what will the COPD/Asthma landscape look like 5 years from now?
The global asthma and COPD market is currently worth around US$20 billion. The top twelve pharmaceutical products by value had combined global sales of US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion. Combined sales of the top ten products were 21.1% higher than in 2004.
A number of older therapies, for asthma in particular, are widely available generically and there is fierce competition in the market. The asthma market accounts for the majority of the total and is valued at around US$15 billion. The COPD market is currently valued at US$4 – US$5 billion and is set to double in the next five years.
Future market growth will be driven by increasing disease awareness, an increasing patient pool, both in the paediatric asthma sector and the ageing population susceptible to COPD, and the launch of newer, more expensive therapies targeting areas of high unmet clinical need. These will be offset to some extent by the launch of new generics and the sales erosion of monotherapies by combination products.
Providing… - Product/Market Forecast by value 2006/2011 for current and future therapies - 15 key products assessed - Market Context - Competitive Evaluation - Research Reviews
